2022 Financial Guidance

Financial Performance Trend Statutory (As Reported) and Pro Forma Revenue¹ ($M) $790.4 Pro Forma ■As Reported $741.8 $763.3 $308.5 $221.0 $245.6 FY2019 Maintenance CAPEX³ ($M) FY2020 Q3'21 TTM AKUMIN Adjusted EBITDA² ($M) ■Pro Forma ■As Reported $159.2 $167.9 $173.4 $52.9 $42.1 $30.1 FY2019 FY2020 Q3'21 TTM Growth CAPEX³ ■Growth (Cons) Pro Forma Growth (Cons) As Reported ■Maint (Cons) Pro Forma ■Maint (Cons) As Reported ($M) $28.9 $17.2 $22.6 $21.0 $5.9 $5.3 FY2019 FY2020 $8.5 Q3'21 TTM $0.0 FY2019 $15.3 $0.0 FY2020 $8.1 $2.7 Q3'21 TTM 1 Pro forma includes Alliance Oncology of Arizona (divested Q4 2021) which contributed $13.2M of Revenue TTM and Interventional Division (divested first half 2021) which contributed $18.4M TTM. Both segments were divested. 2 Pro forma includes Alliance Oncology of Arizona (divested Q4 2021) which contributed ($3.0M) of Adjusted EBITDA TTM and Interventional Division (divested first half 2021) which contributed $1.1M Adjusted EBITDA TTM. Both segments were divested. Adjusted EBITDA is not a standardized financial measure under GAAP and might not be comparable to similar financial measures disclosed by other issuers. See "Non-GAAP Measures" and "How We Assess the Performance of Our Business" in our Interim MD&A. See page 29 for definition of Adjusted EBITDA. 3 Capex may be financed with cash, capital leases, change in deposits and AP. 21

View entire presentation